Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
12 studies found for:    Ipatasertib OR GDC-0068
Show Display Options
Rank Status Study
1 Recruiting A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
2 Completed Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Condition: Cancer
Interventions: Drug: Ipatasertib (capsule);   Drug: Ipatasertib (tablet)
3 Active, not recruiting A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
Condition: Breast Neoplasms
Interventions: Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
4 Completed
Has Results
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Condition: Neoplasms
Interventions: Drug: Ipatasertib;   Drug: Cobimetinib
5 Completed A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers
Condition: Healthy Volunteer
Interventions: Drug: ipatasertib (Capsule);   Drug: ipatasertib (Tablet)
6 Completed A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
Condition: Solid Cancers
Intervention: Drug: GDC-0068
7 Completed A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects
Condition: Healthy Volunteer
Interventions: Drug: Period 1 treatment;   Drug: Period 2 treatment
8 Active, not recruiting A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Condition: Gastric Cancer
Interventions: Drug: 5-Fluorouracil;   Drug: GDC-0068;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Placebo
9 Active, not recruiting Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Condition: Neoplasms
Interventions: Drug: 5-FU;   Drug: Docetaxel;   Drug: Enzalutamide;   Drug: GDC-0068;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Paclitaxel
10 Recruiting Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Drug: Ipatasertib;   Drug: Abiraterone;   Drug: Placebo
11 Active, not recruiting Study of Ipatasertib or GDC-0980 With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone;   Drug: GDC-0980;   Drug: Ipatasertib;   Drug: Placebo;   Drug: Prednisone;   Drug: Prednisolone
12 Enrolling by invitation Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Condition: Glioblastoma
Interventions: Drug: MK - 3475;   Biological: Suppressor of the PI3K/Akt pathways

Study has passed its completion date and status has not been verified in more than two years.